Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
arcticnovartis

  • There is currently no evidence-based treatment for the smallest babies with malaria
  • The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg
  • The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review

Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from the

/by

Novartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal

Novartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR 

/by

Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1  

Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1  
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Europe talks health sovereignty — now it must deliver

Europe talks health sovereignty — now it must deliver
angilma1

/by

Europe talks health sovereignty — now it must deliver

Europe talks health sovereignty — now it must deliver
angilma1

/by

Europe talks health sovereignty — now it must deliver

Europe talks health sovereignty — now it must deliver
angilma1

/by

Science in Motion: Autumn and Sabrina’s Noteworthy Novartis Adventure

Science in Motion: Autumn and Sabrina’s Noteworthy Novartis Adventure
hajdola1

/by

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
arcticnovartis

 Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
arcticnovartis

  • After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of Novartis
  • Karen Hale to drive the next phase of enterprise alignment for our Legal and ERC functions
/by

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by